Ozempic's Promise and Pitfalls: Safety, Caution, and Unanswered Questions

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

Ozempic's Promise and Pitfalls: Safety, Caution, and Unanswered Questions

Ascolta gratuitamente

Vedi i dettagli del titolo

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.

# Ozempic News Roundup: Safety Warnings, Vision Risks, Counterfeit Drugs & Anti-Aging Research **Episode Description:** Ozempic and semaglutide are back in the headlines—and this week's developments demand attention from anyone considering or currently using GLP-1 medications. In this episode of *Navigating Ozempic*, we break down five critical stories reshaping the conversation around semaglutide, tirzepatide, and Mounjaro. **What You'll Learn:** - **Global safety alert**: Namibia's Ministry of Health issues new guidance on ethical prescribing and monitoring for semaglutide and tirzepatide amid surging demand - **Counterfeit drug danger**: Medical Daily investigates online sellers offering cheap "research-grade" semaglutide—some linked to chemicals used in fentanyl production—and why the FDA considers these products unapproved and potentially dangerous - **Vision and pancreatitis risks**: NPR's deep dive into nearly 2,000 pancreatitis cases and 1,000 reports of sudden vision loss (NAION) tied to GLP-1 medications since 2024 - **New pediatric guidelines**: The WHO's first-ever global recommendations for treating childhood obesity, including strict limits on medication use in children and teens - **Nutrition during weight loss**: Why reduced appetite on Ozempic may lead to protein, vitamin, and hydration deficiencies—and what dietitians recommend - **Muscle preservation research**: A promising phase 2 study on trevogrumab, designed to protect lean muscle mass during semaglutide-driven weight loss - **Anti-aging buzz**: Novo Nordisk and Eli Lilly's preliminary research suggesting semaglutide may slow biological aging markers by 2-4 years—and why these early findings need serious scrutiny - **Future of gener Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai

Ancora nessuna recensione